Watson Strides into Australian, SE Asian generics markets with $393m Ascent
This article was originally published in Scrip
Watson Pharmaceuticals has snapped up Strides Arcolab's Australian and Southeast Asian generics business for Aus$375 million ($393 million), catapulting the US firm to fifth position in the growing Australian generics market by revenue and giving it the top slot in Singapore.
You may also be interested in...
Eris Lifesciences has acquired a Novartis trademark for vildagliptin, a DPP-4 inhibitor that has been the subject of a torrent of alleged infringement-related legal action in India. Pricing for the acquired brand will be interesting to watch from now on as a patent on vildagliptin is set to expire soon.
Cipla’s global chief operating officer is leaving the company to pursue new interests, amid a spate of top-level exits that have marked the pharma sector in India in 2019.